

**510(k) Summary**

K110167  
P1/2

**Submitter:** Edwards Lifesciences LLC  
One Edwards Way  
Irvine, CA 92614-5686

FEB 18 2011

**Contact Person:** Marguerite Thomlinson, JD, BSME  
Sr. Manager of Regulatory Affairs  
Edwards Lifesciences LLC  
Phone: (949) 756-4386  
Fax: (949) 809-5676

**Date Prepared:** February 17, 2011

**Trade Name:** PreSep Oligon Oximetry Catheters

**Classification Name:** Catheter, Oximeter, Fiberoptic (21 CFR Part 870.1230)

**Product Class/ Code:** Class II/ DQE

**Predicate Devices:** K060093, PreSep Oligon Oximetry Catheters  
K100739, VolumeView System

**Device Description:**

The PreSep Oligon Oximetry Catheters (K060093) are used with Edwards oximetry monitors to continuously measure oxygen saturation. The catheters also provide the means for infusion of solutions, measuring pressure and taking blood samples. The PreSep Oligon Oximetry Catheters can be used with an uncoated stainless steel guidewire or a PTFE-coated Nitinol core guidewire, which are included in kits or as separately packaged components.

**Indications for Use:**

The PreSep Oligon Oximetry Catheters are indicated for hemodynamic monitoring through blood sampling, pressure monitoring and oxygen saturation measurements.

**Comparative Analysis:**

Verification and validation testing was conducted to compare the performance and functionality of the PreSep Oligon Oximetry Catheters to the predicate device. This testing regimen included side-by-side comparative bench and pre-clinical performance testing of the pending and predicate devices. The results show that the

## 510(k) Summary

K110167  
P 2/2

performance functionality of the pending guidewire is substantially equivalent to the predicate device, and provides a marked improvement in the ease of use of the pending device in comparison to the predicate device. Thus, the PreSep Oligon Oximetry Catheters have been demonstrated to be safe and effective and substantially equivalent to the predicate device for their intended use.

### **Functional/Safety Testing:**

The PreSep Oligon Oximetry Catheters have successfully undergone functional and performance testing, including bench studies, pre-clinical animal studies and biocompatibility testing. The PreSep Oligon Oximetry Catheters have been shown to be safe and effective and substantially equivalent to the cited predicate device for their intended use.

### **Conclusion:**

The PreSep Oligon Oximetry Catheters are safe and effective and are substantially equivalent to the cited predicate device.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room - WO66-G609  
Silver Spring, MD 20993-0002

Edwards Lifesciences, LLC  
C/O Ms. Marguerite Thomlinson  
Sr. Manager of Regulatory Affairs, Critical Care  
One Edwards Way  
Irvine, CA 92614

FEB 18 2011

Re: K110167

Trade/Device Name: PreSep Oligon Oximetry Catheters  
Regulation Number: 21 CFR 870.1230  
Regulation Name: Catheter, Oximetry, Fiberoptic  
Regulatory Class: Class II  
Product Code: DQE  
Dated: January 18, 2011  
Received: January 20, 2011

Dear Ms. Thomlinson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21


Page 2 – Ms. Thomlinson

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



*For*

Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K110167

Device Name: PreSep Oligon Oximetry Catheters

Indications for Use:

The PreSep Oligon Oximetry Catheters are indicated for hemodynamic monitoring through blood sampling, pressure monitoring and oxygen saturation measurements.

Prescription Use X AND/OR Over-The-Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



**(Division Sign-Off)**  
**Division of Cardiovascular Devices**

510(k) Number K110167